This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): Formoterol fumarate multi-dose dry powder inhaler
Description: Foradil Certihaler is a multi-dose dry powder inhaler version of the long-acting bronchodilator formoterol.
Deal Structure: In November 1998, the SkyePharma and Novartis agreed to jointly develop a new formulation of Novartis' Foradil asthma drug using the SkyePharma's multi-dose dry powder inhaler. SkyePharma is responsible for producing the drug in its finished form, including supplying both the powder and the device as a product to Novartis. Under the arrangement, Novartis has paid SkyePharma technology access fee of 0.4 million and made an equity investment in SkyePharma amounting to 6.1 million. Novartis has also agreed to pay SkyePharma royalty income on future worldwide sales of the drug. In return, SkyePharma has granted Novartis an exclusive worldwide license to market Foradil in the new delivery form.
In the US, the Foradil franchise has been licensed by Novartis to Schering-Plough (Nov 2002).
In March 2009, Merck & Co and Schering-Plough announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine,...See full deal structure in Biomedtracker
Partners: Vectura Group Astellas Pharma, Inc.
Foradil Certihaler News
Pink Sheet June 2010 Supplements
Pink Sheet December 2006 Approvals
Additional information available to subscribers only: